Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin Taylor

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
Nature Medicine|February 20, 2018
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancersMichael Seiler, Akihide Yoshimi, Rachel Darman, et al.
Cell Stem Cell|August 15, 2023
Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowthsMariela Cortés-López, Paulina Chamely, Allegra G Hawkins, et al.
The New England Journal of Medicine|February 23, 2022
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase InhibitorsEric Wang, Xiaoli Mi, Meghan C Thompson, et al.
Discover Oncology|December 21, 2025
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry programAstghik Voskanyan, Maria Badikyan, Marina Konopleva, et al.
American Journal of Hematology|October 17, 2022
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemiaMaximilian Stahl, Andriy Derkach, Noushin Farnoud, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
Blood Reviews|March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.
Blood|July 12, 2024
Risk prediction for clonal cytopenia: multicenter real-world evidenceZhuoer Xie, Rami Komrokji, Najla Al Ali, et al.
Lancet (London, England)|March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.
Leukemia|October 20, 2022
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic SyndromesAmer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
Nature Medicine|February 20, 2018
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancersMichael Seiler, Akihide Yoshimi, Rachel Darman, et al.
Cell Stem Cell|August 15, 2023
Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowthsMariela Cortés-López, Paulina Chamely, Allegra G Hawkins, et al.
The New England Journal of Medicine|February 23, 2022
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase InhibitorsEric Wang, Xiaoli Mi, Meghan C Thompson, et al.
Discover Oncology|December 21, 2025
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry programAstghik Voskanyan, Maria Badikyan, Marina Konopleva, et al.
American Journal of Hematology|October 17, 2022
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemiaMaximilian Stahl, Andriy Derkach, Noushin Farnoud, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
Blood Reviews|March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.
Blood|July 12, 2024
Risk prediction for clonal cytopenia: multicenter real-world evidenceZhuoer Xie, Rami Komrokji, Najla Al Ali, et al.
Lancet (London, England)|March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.
Leukemia|October 20, 2022
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic SyndromesAmer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, et al.
Pageof 14